The National Viral Hepatitis Control Programme (NVHCP), launched by India's Ministry of Health and Family Welfare in 2018, has now completed eight years of operation. This public health initiative represents one of the most comprehensive efforts to tackle viral hepatitis in the country, focusing on prevention, testing, treatment, and awareness of hepatitis B and C infections.
Understanding Viral Hepatitis
Viral hepatitis refers to inflammation of the liver caused by five main virus types: A, B, C, D, and E. Among these, hepatitis B and C are particularly concerning as they can become chronic conditions, potentially leading to cirrhosis, liver cancer, and liver failure. India carries one of the highest burdens of hepatitis globally, with an estimated 40 million people living with chronic hepatitis B and 6-12 million with chronic hepatitis C.
The disease often progresses silently, with many infected individuals showing no symptoms until significant liver damage has occurred. This makes early detection and treatment crucial for preventing serious complications and reducing transmission within communities.
Key Components of the Programme
The NVHCP operates through a multi-pronged approach designed to address hepatitis at various levels of the healthcare system. The programme integrates services within existing health infrastructure, making diagnosis and treatment more accessible to the general population.
Testing and diagnosis facilities have been established at district hospitals and medical colleges across the country. These centers are equipped to conduct screening tests for hepatitis B and C, allowing for early identification of infected individuals. The programme also emphasizes testing high-risk groups, including healthcare workers, patients requiring frequent blood transfusions, and people who inject drugs.
Treatment under NVHCP is provided free of cost at designated centers. For hepatitis C, the programme offers direct-acting antiviral medications that can cure the infection in 8-12 weeks with minimal side effects. Hepatitis B treatment focuses on antiviral therapy to suppress viral replication and prevent liver damage, though it typically requires longer-term management.
Prevention and Vaccination Efforts
Prevention remains a cornerstone of the programme's strategy. Hepatitis B vaccination has been integrated into the Universal Immunization Programme, ensuring that all newborns receive the birth dose within 24 hours of delivery, followed by additional doses at 6, 10, and 14 weeks of age. This birth-dose coverage is critical for preventing mother-to-child transmission.
The programme also emphasizes safe injection practices, blood safety measures, and infection control protocols in healthcare settings. Educational campaigns aim to raise awareness about transmission routes, which include contaminated blood, unsafe injection practices, unprotected sexual contact, and mother-to-child transmission during childbirth.
Challenges and Progress
Despite significant achievements, the programme faces several challenges. Limited awareness about hepatitis among the general population often results in late diagnosis when liver damage is already advanced. Many people remain unaware of their infection status due to the asymptomatic nature of the disease in its early stages.
Infrastructure gaps in rural and remote areas can limit access to diagnostic and treatment facilities. The programme continues to work on expanding its reach by training healthcare workers and establishing more testing centers at the primary healthcare level.
Contact tracing and screening of family members of infected individuals remains an area requiring strengthened efforts. Since hepatitis B can spread through household contact, identifying and vaccinating close contacts is essential for breaking transmission chains.
Looking Forward
As the programme marks eight years, the focus remains on achieving the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030. This requires scaling up screening efforts, ensuring universal access to treatment, and maintaining high vaccination coverage.
The integration of hepatitis services with other health programmes, such as those for HIV and tuberculosis, offers opportunities for more efficient service delivery. Digital health technologies and data management systems are being leveraged to improve tracking of patients and programme outcomes.
Community engagement and awareness campaigns continue to play a vital role in reducing stigma associated with hepatitis and encouraging people to get tested. Early diagnosis and treatment not only benefit individual patients but also prevent further transmission, contributing to broader public health goals.
This article is for general information purposes only. Individuals concerned about hepatitis or seeking testing and treatment should consult qualified healthcare professionals or visit designated health facilities under the National Viral Hepatitis Control Programme.
